Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is a multi-centre European Phase 1 study of MEK1/2 inhibitor PD-0325901 with c-MET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients.

A Sequential Phase I study of MEK 1/2 inhibitors PD-0325901 or Binimetinib combined with cMET inhibitor PF-02341066 in Patients with RAS Mutant and RAS Wild Type (with aberrant c-MET) Colorectal Cancer

Primary Objectives

Dose Escalation Phase: To assess the safety and toxicity profile of PD-0325901 or Binimetinib/PF-02341066 combination in patients with advanced solid tumours using the NCI CTCAE V4.03, and determine the maximum tolerated dose (MTD).

Dose Expansion Phase: To investigate the response to treatment with RPII dose of PF-02341066 in combination with Binimetinib in patients with RASMT and RASWT/c-MET+ CRC.

Our team

  • Sarah Pearson

    OCTO Trial Management Director